FDA adds two Roche stud­ies to its grow­ing list of par­tial clin­i­cal holds in wake of Keytru­da deaths

Alarmed that an im­bal­ance in deaths among pa­tients tak­ing a com­bi­na­tion of Keytru­da with Cel­gene’s Po­m­a­lyst and Revlim­id could rep­re­sent a threat in that whole …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.